21 May 2013
Keywords: Par Pharma, Edict Pharma, M&A, Generics
Article | 24 May 2011
US generics and niche drug company Par Pharmaceutical (NYSE: PRX) has entered into a definitive agreement to acquire privately-held Chennai, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 May 2011
23 May 2011
20 May 2013
© 2013 thepharmaletter.com